{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:21:17Z","timestamp":1785320477819,"version":"3.55.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Seasonal influenza leads to 2\u20133 million infections and up to 650,000 global deaths annually, with particularly high mortality in Asia and relatively low annual vaccination rates for prevention. Relatively lower attention is paid to antiviral treatment as a facet of influenza response strategy both in research and national policy. This study compares national influenza treatment guidelines across countries in the Asia Pacific region, and assesses the antiviral recommendations, comprehensiveness, availability, and quality, compared with World Health Organisation (WHO) guidelines. Ministry of Health websites were searched, and key stakeholders were contacted to obtain national influenza treatment guidelines. Official guidelines detailing pharmacologic treatment for seasonal influenza were included. Key data for comparison were extracted and quality appraisal was conducted using the AGREE II instrument. Out of 49 countries and areas in the World Health Organisation Western Pacific and South-East Asia regions, under half (14\/49; 28.6%) had established national influenza treatment guidelines. Nine (9\/49; 18.4%) reported no seasonal flu guidelines at all, and information could not be obtained for 25 (51.0%). All guidelines recommend oseltamivir in line with WHO recommendations, although rationale and evidence reviews were often missing. There was variation in recommendations for other antivirals, indications for treatment, definitions of severity and recency of publication. The AGREE II tool quality assessments revealed the highest average scores were observed in the \u2018presentation\u2019 domain and lowest scores in \u2018editorial independence\u2019 and \u2018rigour of development\u2019 domains, demonstrating limited evidence-based guideline development. The variability in recommendations and definitions highlight the need for a stronger evidence base with direct comparisons of antiviral treatment for hard and soft endpoints, and improvements in systematic guideline development. Established treatment guidelines are a key component of national influenza response strategy and in the post-covid pandemic era, renewed attention to seasonal influenza management is surely warranted.<\/jats:p>","DOI":"10.1371\/journal.pgph.0004468","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:22:47Z","timestamp":1745860967000},"page":"e0004468","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["A comparison of national seasonal influenza treatment guidelines across the Asia Pacific region"],"prefix":"10.1371","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3645-7884","authenticated-orcid":true,"given":"Ellen","family":"Beer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8731-5499","authenticated-orcid":true,"given":"Simon","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phrutsamon","family":"Wongnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thundon","family":"Ngamprasertchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-1978","authenticated-orcid":true,"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"10127","key":"pgph.0004468.ref001","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"AD Iuliano","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"pgph.0004468.ref002","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/irv.12496","article-title":"Estimated incidence of influenza-associated severe acute respiratory infections in Indonesia, 2013-2016","volume":"12","author":"NK Susilarini","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"issue":"10","key":"pgph.0004468.ref003","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3201\/eid2710.204765","article-title":"Burden of influenza-associated respiratory hospitalizations, Vietnam, 2014-2016","volume":"27","author":"NC Khanh","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"pgph.0004468.ref004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/irv.12223","article-title":"Estimating influenza outpatients\u2019 and inpatients\u2019 incidences from 2009 to 2011 in a tropical urban setting in the Philippines","volume":"8","author":"VL Tallo","year":"2014","journal-title":"Influenza Other Respir Viruses"},{"issue":"5","key":"pgph.0004468.ref005","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/heapol\/czr056","article-title":"Avian and pandemic human influenza policy in South-East Asia: the interface between economic and public health imperatives","volume":"27","author":"P Pongcharoensuk","year":"2012","journal-title":"Health Policy Plan"},{"issue":"6","key":"pgph.0004468.ref006","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.vaccine.2016.12.064","article-title":"Influenza in the Asia-Pacific region: Findings and recommendations from the Global Influenza Initiative","volume":"35","author":"BJ Cowling","year":"2017","journal-title":"Vaccine"},{"issue":"35","key":"pgph.0004468.ref007","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1016\/j.vaccine.2019.07.011","article-title":"Acceptance and uptake of influenza vaccines in Asia: a systematic review","volume":"37","author":"A Sheldenkar","year":"2019","journal-title":"Vaccine"},{"key":"pgph.0004468.ref008","doi-asserted-by":"crossref","first-page":"1171975","DOI":"10.3389\/fpubh.2023.1171975","article-title":"Characteristics of clinical trials of influenza and respiratory syncytial virus registered in ClinicalTrials.gov between 2014 and 2021","volume":"11","author":"D Lora","year":"2023","journal-title":"Front Public Health"},{"issue":"8","key":"pgph.0004468.ref009","doi-asserted-by":"crossref","first-page":"e2119151","DOI":"10.1001\/jamanetworkopen.2021.19151","article-title":"Comparison of antiviral agents for seasonal influenza outcomes in healthy adults and children: a systematic review and network meta-analysis","volume":"4","author":"J-W Liu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"pgph.0004468.ref010","author":"Infectious Diseases Data Observatory.","year":"2024"},{"issue":"8","key":"pgph.0004468.ref011","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJMp068030","article-title":"Antiviral resistance in influenza viruses--implications for management and pandemic response","volume":"354","author":"FG Hayden","year":"2006","journal-title":"N Engl J Med"},{"issue":"9492","key":"pgph.0004468.ref012","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern","volume":"366","author":"RA Bright","year":"2005","journal-title":"Lancet"},{"key":"pgph.0004468.ref013","author":"United States Food & Drug Administration.","year":"1999"},{"issue":"9218","key":"pgph.0004468.ref014","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial.","volume":"355","author":"KG Nicholson","year":"2000","journal-title":"The Lancet"},{"issue":"8","key":"pgph.0004468.ref015","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"JJ Treanor","year":"2000","journal-title":"JAMA"},{"issue":"13","key":"pgph.0004468.ref016","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment","volume":"282","author":"FG Hayden","year":"1999","journal-title":"JAMA"},{"issue":"3","key":"pgph.0004468.ref017","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/135965350000500305","article-title":"Oral oseltamivir in human experimental influenza B infection","volume":"5","author":"FG Hayden","year":"2000","journal-title":"Antivir Ther"},{"issue":"10217","key":"pgph.0004468.ref018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(19)32982-4","article-title":"Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. The","volume":"395","author":"CC Butler","year":"2020","journal-title":"Lancet"},{"key":"pgph.0004468.ref019","volume-title":"Guidelines for the clinical management of severe illness from influenza virus infections","author":"World Health Organization.","year":"2021"},{"key":"pgph.0004468.ref020","doi-asserted-by":"crossref","first-page":"g2371","DOI":"10.1136\/bmj.g2371","article-title":"Oseltamivir: the real world data","volume":"348","author":"N Freemantle","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"pgph.0004468.ref021","doi-asserted-by":"crossref","first-page":"00888","DOI":"10.1183\/23120541.00888-2020","article-title":"Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia","volume":"7","author":"G Moreno","year":"2021","journal-title":"ERJ Open Res"},{"issue":"9979","key":"pgph.0004468.ref022","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"J Dobson","year":"2015","journal-title":"Lancet"},{"key":"pgph.0004468.ref023","volume-title":"The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2021 (including the 22nd WHO Model List of Essential Medicines and the 8th WHO Model List of Essential Medicines for Children","author":"World Health Organisation.","year":"2021"},{"issue":"1","key":"pgph.0004468.ref024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3201\/eid1601.091304","article-title":"Oseltamivir- and amantadine-resistant influenza virus A (H1N1)","volume":"16","author":"PK Cheng","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"9144","key":"pgph.0004468.ref025","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(98)10190-3","article-title":"Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections","volume":"352","author":"The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"pgph.0004468.ref026","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00474-10","article-title":"Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection","volume":"54","author":"S Kohno","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pgph.0004468.ref027","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00360-11","article-title":"Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection","volume":"55","author":"S Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pgph.0004468.ref028","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial","volume":"51","author":"MARVEL Study Group.","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pgph.0004468.ref029","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"FG Hayden","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"pgph.0004468.ref030","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"MG Ison","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pgph.0004468.ref031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.02.007","article-title":"Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018","volume":"164","author":"P Koszalka","year":"2019","journal-title":"Antiviral Res"},{"issue":"10","key":"pgph.0004468.ref032","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","article-title":"Favipiravir treatment of uncomplicated influenza in adults: results of two Phase 3, randomized, double-blind, placebo-controlled trials","volume":"226","author":"FG Hayden","year":"2022","journal-title":"J Infect Dis"},{"issue":"1","key":"pgph.0004468.ref033","doi-asserted-by":"crossref","first-page":"88","DOI":"10.17116\/terarkh201587188-96","article-title":"Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR","volume":"87","author":"OI Kiselev","year":"2015","journal-title":"Ter Arkh"},{"issue":"2","key":"pgph.0004468.ref034","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/CCM.0000000000004093","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza: an updated cochrane systematic review and meta-analysis","volume":"48","author":"LE Lansbury","year":"2020","journal-title":"Crit Care Med"},{"issue":"4","key":"pgph.0004468.ref035","doi-asserted-by":"crossref","first-page":"e014188","DOI":"10.1136\/bmjgh-2023-014188","article-title":"Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match","volume":"9","author":"M Cokljat","year":"2024","journal-title":"BMJ Glob Health"},{"key":"pgph.0004468.ref036","unstructured":"AGREE Next Steps Consortium. The AGREE II Instrument [Electronic version]. 2009."},{"issue":"4","key":"pgph.0004468.ref037","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4103\/2224-3151.207039","article-title":"Pandemic influenza preparedness planning: lessons from Cambodia","volume":"1","author":"AC Huszar","year":"2012","journal-title":"WHO South East Asia J Public Health"},{"issue":"10","key":"pgph.0004468.ref038","doi-asserted-by":"crossref","first-page":"e0291673","DOI":"10.1371\/journal.pone.0291673","article-title":"Prescription of anti-influenza drugs in Japan, 2014-2020: a retrospective study using open data from the national claims database","volume":"18","author":"A Sako","year":"2023","journal-title":"PLoS One"},{"key":"pgph.0004468.ref039","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1476-072X-11-53","article-title":"An analysis of health system resources in relation to pandemic response capacity in the Greater Mekong Subregion","volume":"11","author":"P Hanvoravongchai","year":"2012","journal-title":"Int J Health Geogr"},{"issue":"2","key":"pgph.0004468.ref040","doi-asserted-by":"crossref","first-page":"e31800","DOI":"10.1371\/journal.pone.0031800","article-title":"Health system resource gaps and associated mortality from pandemic influenza across six Asian territories","volume":"7","author":"JW Rudge","year":"2012","journal-title":"PLoS One"},{"key":"pgph.0004468.ref041","author":"World Health Organization.","year":"2024"},{"issue":"11","key":"pgph.0004468.ref042","first-page":"2392","article-title":"Operationalising regional cooperation for infectious disease control: a scoping review of regional disease control bodies and networks","volume":"11","author":"A Durrance-Bagale","year":"2022","journal-title":"Int J Health Policy Manag"},{"issue":"12","key":"pgph.0004468.ref043","first-page":"3141","article-title":"What can we learn from others to develop a regional centre for infectious diseases in ASEAN? Comment on \u201cOperationalising regional cooperation for infectious disease control: a scoping review of regional disease control bodies and networks","volume":"11","author":"Y Teerawattananon","year":"2022","journal-title":"Int J Health Policy Manag"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:22:58Z","timestamp":1745860978000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004468"}},"subtitle":[],"editor":[{"given":"Sharmistha","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0004468","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}